SITE001-0068

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-05-12

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 125); relationship: not assessed

severe serious assessed

Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-03 (study day 129); relationship: N; serious criteria: life-threatening

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 145); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-22 (study day 209); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-23 (study day 241); relationship: Y

Data queries

No data queries.